drugset
drugset / Trial / NCT05287360

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

NCT05287360 ↗

Phase 1 Completed 60 enrolled Elevar Therapeutics
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.

Timeline

Start
2021-12-30
Primary completion
2022-03-16
Completion
2022-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 200 mg Oral
Subject Rivoceranib Small molecule 250 mg Oral

Indications

No indication recorded.